American Journal of Clinical Pathology · 1995 · 13 citations · 28 references
MedicineOncologyPathologyCancer ScreeningMolecular PathologyNeoplasiaCancer DetectionCancer DiagnosisCancer Molecular DiagnosticsCancer Molecular PathologyLung CancerTumor DetectionLung Biopsy DiagnosisLung Cancer PathologyLung Cancer ScreeningP53 AbnormalityPolymerase Chain Reaction (Pcr)-based Diagnosis
Malignant neoplasms possess multiple genetic abnormalities. Among those, p53 gene abnormalities are the most frequent in human neoplasms. To screen for p53 abnormalities, both immunohistochemistry (IHC) and the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) methods are commonly used, but neither can detect specimens simultaneously by the two methods, 12 abnormal cases (34%) were detected by IHC and 9 abnormal cases (26%) were detected by PCR-SSCP. Six abnormal (17%) and 20 normal (57%) cases showed concordant results between the methods, although 9 cases (26%) showed discordance, including 6 IHC-positive cases (17%) and 3 SSCP-positive cases (9%). Because it is known that some p53 abnormalities are detected only by IHC or only by PCR-SSCP, discordant cases should be assessed as possessing abnormalities. Fifteen cases (43%) were finally assessed as abnormal. These results suggest that the two methods together can increase the sensitivity of screening for p53 abnormalities.
28
WAF1, a potential mediator of p53 tumor suppression
Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell · 1993 · 8.4K citations
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
David Malkin, Frederick P. Li, Louise C. Strong et al. · Science · 1990 · 3.8K citations
Life Sciences, Genetics, Oncology +17
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Marc S. Greenblatt, W P Bennett, Monica Hollstein et al. · PubMed · 1994 · 3.5K citations